Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation

Rhea-AI Summary

Cannabis Bioscience International Holdings (OTC Pink: CBIH) has reached a historic 2 billion dollar valuation, reflecting over 15 years of dedication to medicinal cannabis research. The company emphasizes its commitment to enhancing healthcare standards and promoting cannabinoids as primary treatment options. CEO Dante Picazo shares enthusiasm about future advancements in healthcare. CBIH integrates neuroscience principles to revolutionize medicine and offers groundbreaking solutions globally. The company aims to expand its market presence and innovate new therapeutic alternatives, reaffirming its commitment to excellence in the cannabis industry.

Positive

• Achieved a historic 2 billion dollar valuation.
• Over 15 years dedicated to medicinal cannabis research.
• Commitment to enhancing healthcare standards.
• Promotion of cannabinoids as primary treatment options.
• Integration of neuroscience principles to revolutionize medicine.
• CEO expresses enthusiasm for future healthcare advancements.
• Global approach with groundbreaking solutions.
• Focused on expanding market presence and innovating new therapeutic alternatives.

Negative

• No specific financial performance metrics or revenue figures provided.
• Lack of detailed clinical trial results or efficacy data.
• Potential market risks associated with the cannabis industry not addressed.
• Unclear how the valuation impacts current shareholder value or future growth.

HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation. This achievement is a testament of the paradigm shift which will allow patients and the medical industry to consider cannabinoids as the first option, not a last resource.

Our significant valuation is the outcome of our unwavering dedication to growth and our persistent commitment to enhancing standards within the healthcare landscape. With a steadfast focus on maintaining market integrity and propelling scientific evolution, our CEO, Dante Picazo, shares his enthusiasm: "Together, we're paving the way for the future of healthcare, and we're enthusiastic about embarking on this shared adventure of advancement."

At CBIH, we embrace a global approach that integrates neuroscience principals, which are revolutionizing modern medicine with clinical, social, and personal implications by understanding the neural-physical relationship, says Dr. Salguero PhD in Science specialized in Microbiology from São Paulo Brazil University.

To conclude, our tireless dedication to excellence compels us to fortify our message daily with groundbreaking and premium solutions for those who depend on us for their well-being. Cannabis Bioscience International Holdings stands optimally positioned to advance its market footprint, innovate fresh therapeutic alternatives, and reassert its unwavering commitment to innovation and excellence in the cannabis industry. Moving ahead, we maintain relentless resolve in our pursuit to redefine norms and positively influence the future landscape of cannabis-based wellness.

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

FAQ

What is the significance of the 2 billion dollar valuation achieved by CBIH?

The 2 billion dollar valuation reflects Cannabis Bioscience International Holdings' dedication to medicinal cannabis research over 15 years and its commitment to enhancing healthcare standards.

How does Cannabis Bioscience International Holdings plan to use its historic valuation?

CBIH aims to expand its market presence, innovate new therapeutic alternatives, and uphold its commitment to excellence in the cannabis industry.

What are the future plans of CBIH according to its CEO?

CEO Dante Picazo expressed enthusiasm about future healthcare advancements and emphasized the company's focus on promoting cannabinoids as primary treatment options.

How is CBIH revolutionizing modern medicine?

CBIH integrates neuroscience principles to understand the neural-physical relationship, which is important for advancing clinical, social, and personal healthcare solutions.

What is the global approach of Cannabis Bioscience International Holdings?

CBIH embraces a global approach by offering groundbreaking solutions and integrating advanced scientific principles to improve patient well-being.